Detalhe da pesquisa
1.
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
Lancet Oncol
; 23(3): 374-381, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35157829
2.
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Lancet Oncol
; 22(11): 1530-1540, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34656227
3.
BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms.
Oncogene
; 42(8): 572-585, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36550359
4.
Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial.
EClinicalMedicine
; 48: 101432, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35706488
5.
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.
Lancet Respir Med
; 9(6): 593-600, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33515503
6.
Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment.
Nat Commun
; 12(1): 1751, 2021 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33741915
7.
Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment.
Nat Commun
; 12(1): 3569, 2021 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34099722